LAVA Therapeutics (NASDAQ:LVTX – Get Free Report) is anticipated to post its quarterly earnings results before the market opens on Wednesday, March 19th. Analysts expect LAVA Therapeutics to post earnings of ($0.32) per share and revenue of $2.40 million for the quarter.
LAVA Therapeutics Price Performance
NASDAQ:LVTX opened at $1.30 on Monday. LAVA Therapeutics has a 12-month low of $0.85 and a 12-month high of $4.21. The firm has a market capitalization of $34.19 million, a P/E ratio of -1.26 and a beta of 0.48. The business has a 50 day simple moving average of $1.07 and a 200 day simple moving average of $1.39.
Analyst Ratings Changes
A number of research analysts recently issued reports on the company. Leerink Partnrs lowered LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, December 12th. Citizens Jmp lowered LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, December 11th. JMP Securities reiterated a “market perform” rating and set a $6.00 price target on shares of LAVA Therapeutics in a research report on Wednesday, December 11th. Leerink Partners reiterated a “market perform” rating and set a $2.00 price target (down previously from $11.00) on shares of LAVA Therapeutics in a research report on Thursday, December 12th. Finally, HC Wainwright reiterated a “neutral” rating and set a $1.50 price target (down previously from $2.00) on shares of LAVA Therapeutics in a research report on Thursday, February 27th. Five equities research analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $3.17.
LAVA Therapeutics Company Profile
LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.
Featured Articles
- Five stocks we like better than LAVA Therapeutics
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- How to Build the Ultimate Everything ETF Portfolio
- What is a Dividend King?
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- 3 Ways To Invest In Coffee, Other Than Drinking It
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for LAVA Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LAVA Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.